Berger Montague PCis investigating claims under the federal securities laws againstAltimmune, Inc. (NASDAQ: ALT) (“Altimmune” or the “Company”), aclinical-stage biopharmaceutical companyfocused on developing therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) after a class action lawsuit was filed against Altimmune.
https://mma.prnewswire.com/media/232479/berger_montague.jpg
Investor Deadline:Investors who purchased or acquired Altimmune securities between August 10, 2023 through June 25, 2025 (the “Class Period”) may, no later than October 6, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
OnJune 26, 2025, Altimmune issued a press release announcingtopline results from its IMPACT Phase 2b trialofPemvidutidefor the treatment of MASH. Despite management's repeated positive statements ahead of the results, the Company revealed afailure to achieve statistical significance in the fibrosis reduction primary endpoint, citing ahigher-than-expected placebo response. While a positive trend was observed, this key metric fell short. When asked about the failure, the Company's executives attributed the shortcoming to the trial's Phase 2 nature and expressed optimism about the Phase 3 trial instead.
In reaction to this news, Altimmune's stock price plunged from a close of $7.71 on June 25, 2025, to a close of $3.61 on June 26 – a one-day decline of more than53% in a single day.
If you are an Altimmune investor and would like to learn more about this action, CLICK HEREor please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger MontagueBerger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto, has been a pioneer in securities class action litigationsince its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:Andrew Abramowitz, Senior CounselBerger Montague(215) 875-3015aabramowitz@bergermontague.com
Caitlin AdorniBerger Montague(267) 764-4865cadorni@bergermontague.com
https://edge.prnewswire.com/c/img/favicon.png?sn=DC83594&sd=2025-09-25
View original content to download multimedia:https://www.prnewswire.com/news-releases/altimmune-nasdaq-alt-class-action-deadline-approaching-berger-montague-advises-investors-to-inquire-about-a-securities-fraud-class-action-by-october-6-2025-302567466.html
SOURCE Berger Montague
https://rt.newswire.ca/rt.gif?NewsItemId=DC83594&Transmission_Id=202509251721PR_NEWS_USPR_____DC83594&DateId=20250925